Bolt Biotherapeutics

BOLT

6.27049.64% ( +2.080 )

Closed: Oct 23, 16:00:00 (EDT)

Q2 FY2026 EarningsQ2 FY2026 results missed top-line consensus significantly with revenue of $5K vs. $500K expected. However, the company beat on bottom-line metrics, reporting a net loss of $7.72M vs. $5.56M expected (lower loss in absolute terms), and a GAAP EPS of -$4.57 vs. -$21.06 expected, primarily driven by aggressive cost-cutting through restructuring. Cash reserves of $18.1M are projected to fund operations into Q1 2027, with high-stakes clinical data for BDC-4182 expected in Q3 2026.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Bolt Biotherapeutics(BOLT) the Revenue is 5 K (-99.72%), Miss estimate;the EBIT is -8.374 M (+9.08%), Miss estimate;the EPS is -4.57 (-2.47%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueMiss expectations

0.00B99.72%

0.00B72.28%

-0.00B27.44%

EBITMiss expectations

-0.01B9.08%

-0.01B32.63%

-0.00B23.55%

EPSExceed expectations

-4.572.47%

-21.0567372.12%

+16.4867369.65%

Upcoming earnings report - FY2026 Q3 Earning Release

Available dateNov 12, 2026

Estimate Revenue450 K

Estimate EBIT-6.3 M

Estimate EPS-3.685

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly